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DMARDs = disease-modifying antirheumatic drugs; NSAIDs = non-steroidal anti-inflammatory drugs; RA = rheumatoid arthritis; TNF = tumor necrosis
factor.
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Introduction
The past decade has been marked by significant
advances in rheumatology, including a better understand-
ing of the pathophysiology of rheumatic diseases and the
addition of agents to the therapeutic armamentarium.
Studies in cell biology and molecular immunology have
clarified the role of cellular and humoral immunity and
related processes in the pathogenesis of rheumatoid
arthritis (RA) and other inflammatory arthritides. Tumor
necrosis factor (TNF) has been identified as a major effec-
tor of structural joint disease in patients with RA and the
spondyloarthropathies, and the development and introduc-
tion of TNF antagonists is a major advance in the manage-
ment of RA. Notably, the successful use of these agents
has not been limited to RA: inroads have been made into
other immune-mediated inflammatory diseases, including
ankylosing spondylitis and psoriatic arthritis.
The efficacy of the TNF antagonists has been established,
and these agents can now be considered the new stan-
dard of care for RA and the spondyloarthropathies when
disease activity is not controlled by standard non-steroidal
anti-inflammatory drugs (NSAIDs) and disease-modifying
antirheumatic drugs (DMARDs). Additionally, much has
been learned about the safety and adverse event profiles
of the TNF antagonists; importantly, we are becoming
more adept at managing safety-related issues. With
appropriate risk management, the TNF antagonists can be
considered to be as safe as the traditional DMARDs and
other anti-inflammatory agents.
However, certain questions remain to be answered. Why
are some patients not completely responsive to anti-TNF
therapy regardless of which TNF antagonist is used? How
can we identify patients who are most likely to respond to
anti-TNF agents? These questions require further investi-
gation. Additionally, remission in most patients with RA
has not yet been achieved; this indicates an unmet need.
Although the TNF antagonists are proving to be effective
and safe therapies for RA, there are other agents in devel-
opment, and some of the preliminary data have been pre-
sented at the 65th American College of Rheumatology
Conference during October 2002 in New Orleans,
Louisiana. When the time comes for such prospective
new therapies to be evaluated, they will have to be com-
pared with the TNF biologic response modifiers, the new
gold standard for the modification of RA.
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